Ligands for imaging cardiac innervation

Abstract

A method of imaging, the method comprising administering, to a subject, a compound of Structure Alpha, of the formula: or a pharmaceutically acceptable salt thereof, wherein: n is 0; R, R1, and R3 are independently selected from the group consisting of H, OR4, F, Cl, Br, I, CF3, alkyl (C1-C4), aryl, heteroaryl, C(═O)R4, CO2R4, N(R4)2, CN, C(═NR4)OR5, NR4C(═NR5)NHR6, C(═NR4)NHR5, C(═O)NHR4, NR4C(═O)NR5, NR4NR5, SO2OR4, and imaging moiety Im; R2 is absent; R4, R5, and R6 are independently selected from the group consisting of H, alkyl, aryl and heteroaryl substituents; wherein the alkyl, aryl, or heteroaryl may be substituted with imaging moiety Im, wherein optionally any two of R4, R5, and R6 form a cyclic structure selected from the group consisting of —CH2—CH2—, —CH2—CH2—CH2, —CH═CH—, —X═CH—, and —X—CH═CH—, wherein X is selected from the group consisting of O, NH, and NR7, and wherein R7 is selected from the group consisting of alkyl, aryl, and heteroaryl substituents; W, X, Y and Z are independently selected from the group consisting of H, OR4, N(R4)2, F, Cl, Br, I, CF3, imaging moiety Im, aryl, and heteroaryl; A is O or absent; and imaging moiety Im is 18F, 76Br, 124I, 131I, 99mTc, 153Gd, or 111In; and acquiring at least one image of the subject.

Dependencies are inferred from the claim text.